echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovent announces a license agreement with Synaffix for antibody-conjugated drug technology

    Innovent announces a license agreement with Synaffix for antibody-conjugated drug technology

    • Last Update: 2021-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cinda Biopharmaceuticals announced the signing of a non-exclusive, target-specific license agreement with Synaffix BV


    According to the terms of the agreement, Synaffix will provide the necessary proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and a certain linker-toxin under its toxSYN™ platform, enabling Innovent to quickly develop its own antibody based on its own antibody and have the best in class Potential ADC candidate molecule


    After the agreement is signed, Cinda Biotech has the right to use the aforementioned ADC technology on the candidate molecule


    According to the agreement, Synaffix will receive the first payment for cooperation and will be eligible to receive milestone payments related to specific R&D progress and sales, as well as future royalties for the ADC product based on commercial net sales


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.